Idiopathic pulmonary disease - GLPG1690

GLPG1690 is a selective autotaxin inhibitor discovered by Galapagos and aimed at idiopathic pulmonary disease (IPF). In a Phase 1 study in healthy human volunteers, GLPG1690 demonstrated favorable safety and tolerability, as well as a strong pharmacodynamic signal implying target engagement. In the FLORA Phase 2a study in IPF patients, Galapagos reported a halt in disease progression, target engagement, and favorable safety and tolerability. GLPG1690 is fully proprietary to Galapagos and has been granted orphan status in Europe and the US.

Related publications

Autotaxin Inhibitor GLPG1690 Affects TGFβ-induced Production of the Pro-Fibrotic Mediators CTGF, IL-6 and ET-1 in Fibroblasts, ATS 2017

Discovery of GLPG1690, a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis, Journal of Medical Chemistry, April 2017

Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor GLPG1690 in a mouse model for IPF, ERS 2016

 Favorable human safety, PK/PD of the autotaxin inhibitor GLPG1690, a potential new treatment in IPF, ATS 2016

 Pharmacological profile and efficacy of GLPG1690, a novel autotaxin inhibitor for the treatment of IPF, ATS 2016

Discovery of GLPG1690: a first-in-class autotaxininhibitor in clinical development for the treatment of IPF at 251st American Chemical Society National Meeting 2016

Poster on pre-clinical data with GLPG1690 at ERS 2015

Oral presentation on pre-clinical data with GLPG1690 at ERS 2015